BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10049263)

  • 1. Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV.
    Akasaka T; Onodera Y; Tanaka M; Sato K
    Antimicrob Agents Chemother; 1999 Mar; 43(3):530-6. PubMed ID: 10049263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
    Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
    Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis.
    Revel-Viravau V; Truong QC; Moreau N; Jarlier V; Sougakoff W
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2054-61. PubMed ID: 8878580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
    Muñoz R; De La Campa AG
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2252-7. PubMed ID: 8891124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.
    Hoshino K; Kitamura A; Morrissey I; Sato K; Kato J; Ikeda H
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2623-7. PubMed ID: 7872758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the gyrB, parC, and parE genes of quinolone-resistant isolates and mutants of Edwardsiella tarda.
    Kim MS; Jun LJ; Shin SB; Park MA; Jung SH; Kim K; Moon KH; Jeong HD
    J Microbiol Biotechnol; 2010 Dec; 20(12):1735-43. PubMed ID: 21193831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS; Yague G; Fisher LM
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
    Mouneimné H; Robert J; Jarlier V; Cambau E
    Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
    Bébéar CM; Grau O; Charron A; Renaudin H; Gruson D; Bébéar C
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2719-27. PubMed ID: 10991851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
    Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.
    Kumagai Y; Kato JI; Hoshino K; Akasaka T; Sato K; Ikeda H
    Antimicrob Agents Chemother; 1996 Mar; 40(3):710-14. PubMed ID: 8851598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and characterization of DNA topoisomerase IV in Escherichia coli.
    Kato J; Suzuki H; Ikeda H
    J Biol Chem; 1992 Dec; 267(36):25676-84. PubMed ID: 1334483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.
    Bébéar CM; Charron A; Bové JM; Bébéar C; Renaudin J
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2024-31. PubMed ID: 9687401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions.
    Peng H; Marians KJ
    J Biol Chem; 1993 Nov; 268(32):24481-90. PubMed ID: 8227000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK; Lee YS; Park YK; Kim BS
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA gyrase and DNA topoisomerase of Bacillus subtilis: expression and characterization of recombinant enzymes encoded by the gyrA, gyrB and parC, parE genes.
    Barnes MH; LaMarr WA; Foster KA
    Protein Expr Purif; 2003 Jun; 29(2):259-64. PubMed ID: 12767818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.